Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

SANOCHEMIA Pharmazeutika

XTRA:SAC
Snowflake Description

Fair value with imperfect balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SAC
XTRA
€1M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

SANOCHEMIA Pharmazeutika AG, a specialty pharmaceuticals company, develops and manufactures drugs and diagnostics in the areas of neurodegeneration, pain, and oncology. The last earnings update was 321 days ago. More info.


Add to Portfolio Compare Print
  • SANOCHEMIA Pharmazeutika has significant price volatility in the past 3 months.
SAC Share Price and Events
7 Day Returns
0%
XTRA:SAC
7.5%
DE Pharmaceuticals
4.3%
DE Market
1 Year Returns
-96.4%
XTRA:SAC
-3.8%
DE Pharmaceuticals
-14.2%
DE Market
SAC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SANOCHEMIA Pharmazeutika (SAC) 0% 0% - -96.4% -96.2% -95.9%
DE Pharmaceuticals 7.5% -7.8% -18% -3.8% 8.7% -6%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • SAC underperformed the Pharmaceuticals industry which returned -3.8% over the past year.
  • SAC underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
SAC
Industry
5yr Volatility vs Market
Related Companies

SAC Value

 Is SANOCHEMIA Pharmazeutika undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of SANOCHEMIA Pharmazeutika to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for SANOCHEMIA Pharmazeutika.

XTRA:SAC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 11.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for XTRA:SAC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.9%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.65
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.646 (1 + (1- 25%) (1670.12%))
6.186
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
2
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (2 * 5.94%)
11.49%

Discounted Cash Flow Calculation for XTRA:SAC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for SANOCHEMIA Pharmazeutika is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

XTRA:SAC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 11.49%)
2020 3.80 Analyst x1 3.41
2021 4.40 Analyst x1 3.54
2022 5.80 Analyst x1 4.19
2023 6.66 Est @ 14.89% 4.31
2024 7.35 Est @ 10.31% 4.27
2025 7.87 Est @ 7.1% 4.10
2026 8.25 Est @ 4.85% 3.86
2027 8.53 Est @ 3.28% 3.57
2028 8.71 Est @ 2.18% 3.27
2029 8.83 Est @ 1.41% 2.98
Present value of next 10 years cash flows €37.00
XTRA:SAC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= €8.83 × (1 + -0.39%) ÷ (11.49% – -0.39%)
€74.07
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €74.07 ÷ (1 + 11.49%)10
€24.96
XTRA:SAC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €37.00 + €24.96
€61.96
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €61.96 / 15.65
€3.96
XTRA:SAC Discount to Share Price
Calculation Result
Value per share (EUR) From above. €3.96
Current discount Discount to share price of €0.07
= -1 x (€0.07 - €3.96) / €3.96
98.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price SANOCHEMIA Pharmazeutika is available for.
Intrinsic value
>50%
Share price is €0.07 vs Future cash flow value of €3.96
Current Discount Checks
For SANOCHEMIA Pharmazeutika to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • SANOCHEMIA Pharmazeutika's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • SANOCHEMIA Pharmazeutika's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SANOCHEMIA Pharmazeutika's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SANOCHEMIA Pharmazeutika's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
XTRA:SAC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in EUR €-1.15
XTRA:SAC Share Price ** XTRA (2020-02-03) in EUR €0.07
Europe Pharmaceuticals Industry PE Ratio Median Figure of 56 Publicly-Listed Pharmaceuticals Companies 21.91x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SANOCHEMIA Pharmazeutika.

XTRA:SAC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:SAC Share Price ÷ EPS (both in EUR)

= 0.07 ÷ -1.15

-0.06x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SANOCHEMIA Pharmazeutika is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • SANOCHEMIA Pharmazeutika is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does SANOCHEMIA Pharmazeutika's expected growth come at a high price?
Raw Data
XTRA:SAC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.06x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 37 Publicly-Listed Pharmaceuticals Companies 1.65x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SANOCHEMIA Pharmazeutika, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SANOCHEMIA Pharmazeutika's assets?
Raw Data
XTRA:SAC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in EUR €2.26
XTRA:SAC Share Price * XTRA (2020-02-03) in EUR €0.07
Germany Pharmaceuticals Industry PB Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 1.77x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
XTRA:SAC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:SAC Share Price ÷ Book Value per Share (both in EUR)

= 0.07 ÷ 2.26

0.03x

* Primary Listing of SANOCHEMIA Pharmazeutika.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SANOCHEMIA Pharmazeutika is good value based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess SANOCHEMIA Pharmazeutika's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. SANOCHEMIA Pharmazeutika has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SAC Future Performance

 How is SANOCHEMIA Pharmazeutika expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
1.4%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is SANOCHEMIA Pharmazeutika expected to grow at an attractive rate?
  • Unable to compare SANOCHEMIA Pharmazeutika's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare SANOCHEMIA Pharmazeutika's earnings growth to the Germany market average as no estimate data is available.
  • SANOCHEMIA Pharmazeutika's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
XTRA:SAC Future Growth Rates Data Sources
Data Point Source Value (per year)
XTRA:SAC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 1.4%
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 13.1%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
XTRA:SAC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
XTRA:SAC Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-09-30 37 1
2023-09-30 37 1
2022-09-30 36 8 1
2021-09-30 36 7 1
2020-09-30 34 6 1
2019-09-30 35 -1 1
XTRA:SAC Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-03-31 34 -5 -16
2018-12-31 34 -2 -15
2018-09-30 34 1 -13
2018-06-30 38 2 -6
2018-03-31 42 4 2
2017-12-31 42 2 1
2017-09-30 42 0 0
2017-06-30 42 0 -1
2017-03-31 42 0 -2
2016-12-31 42 2 -1
2016-09-30 41 3 -1
2016-06-30 40 3 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if SANOCHEMIA Pharmazeutika is high growth as no earnings estimate data is available.
  • SANOCHEMIA Pharmazeutika's revenue is expected to grow by 1.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
XTRA:SAC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from SANOCHEMIA Pharmazeutika Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:SAC Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-09-30
XTRA:SAC Past Financials Data
Date (Data in EUR Millions) EPS *
2019-03-31 -1.15
2018-12-31 -1.10
2018-09-30 -1.03
2018-06-30 -0.46
2018-03-31 0.12
2017-12-31 0.05
2017-09-30 -0.02
2017-06-30 -0.09
2017-03-31 -0.15
2016-12-31 -0.10
2016-09-30 -0.04
2016-06-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • SANOCHEMIA Pharmazeutika is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess SANOCHEMIA Pharmazeutika's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SANOCHEMIA Pharmazeutika has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SAC Past Performance

  How has SANOCHEMIA Pharmazeutika performed over the past 5 years?

  • SANOCHEMIA Pharmazeutika's last earnings update was 321 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SANOCHEMIA Pharmazeutika's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SANOCHEMIA Pharmazeutika does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare SANOCHEMIA Pharmazeutika's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SANOCHEMIA Pharmazeutika's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
SANOCHEMIA Pharmazeutika's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SANOCHEMIA Pharmazeutika Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

XTRA:SAC Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 34.45 -16.45 9.53
2018-12-31 34.14 -14.87 9.32
2018-09-30 33.84 -13.28 9.11
2018-06-30 38.16 -5.87 9.08
2018-03-31 42.48 1.55 9.05
2017-12-31 42.42 0.65 9.20
2017-09-30 42.36 -0.25 9.35
2017-06-30 42.11 -1.11 9.64
2017-03-31 41.87 -1.98 9.92
2016-12-31 41.52 -1.27 9.87
2016-09-30 41.17 -0.56 9.82
2016-06-30 40.05 -0.39 9.59
2016-03-31 38.94 -0.22 9.35
2015-12-31 38.44 0.08 9.41
2015-09-30 37.95 0.38 9.47
2015-06-30 36.76 -0.77 9.89
2015-03-31 35.58 -1.92 10.31
2014-12-31 36.54 -2.66 10.53
2014-09-30 37.50 -3.40 10.74
2014-06-30 39.35 -3.86 18.14
2014-03-31 37.33 -3.15 10.75
2013-12-31 36.78 -2.19 10.57
2013-09-30 36.24 -1.23 10.38
2013-06-30 34.07 -1.46 10.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SANOCHEMIA Pharmazeutika has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SANOCHEMIA Pharmazeutika has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SANOCHEMIA Pharmazeutika improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SANOCHEMIA Pharmazeutika's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SANOCHEMIA Pharmazeutika has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SAC Health

 How is SANOCHEMIA Pharmazeutika's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SANOCHEMIA Pharmazeutika's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SANOCHEMIA Pharmazeutika is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SANOCHEMIA Pharmazeutika's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SANOCHEMIA Pharmazeutika's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SANOCHEMIA Pharmazeutika Company Filings, last reported 1 year ago.

XTRA:SAC Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 35.33 17.16 2.17
2018-12-31 35.33 17.16 2.17
2018-09-30 33.48 17.84 3.85
2018-06-30 33.48 17.84 3.85
2018-03-31 46.83 17.69 3.86
2017-12-31 46.83 17.69 3.86
2017-09-30 46.76 15.72 2.13
2017-06-30 46.76 15.72 2.13
2017-03-31 45.29 24.96 8.91
2016-12-31 45.29 24.96 8.91
2016-09-30 46.95 18.46 6.37
2016-06-30 46.95 18.46 6.37
2016-03-31 47.23 15.36 3.09
2015-12-31 47.23 15.36 3.09
2015-09-30 47.42 14.91 2.68
2015-06-30 47.42 14.91 2.68
2015-03-31 47.47 16.32 1.85
2014-12-31 47.47 16.32 1.85
2014-09-30 46.97 16.66 1.88
2014-06-30 46.97 16.66 1.88
2014-03-31 49.36 16.85 2.50
2013-12-31 49.36 16.85 2.50
2013-09-30 50.59 16.89 3.42
2013-06-30 52.64 15.96 3.27
  • SANOCHEMIA Pharmazeutika's level of debt (48.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (34.1% vs 48.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on SANOCHEMIA Pharmazeutika's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess SANOCHEMIA Pharmazeutika's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SANOCHEMIA Pharmazeutika has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SAC Dividends

 What is SANOCHEMIA Pharmazeutika's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SANOCHEMIA Pharmazeutika dividends.
If you bought €2,000 of SANOCHEMIA Pharmazeutika shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SANOCHEMIA Pharmazeutika's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SANOCHEMIA Pharmazeutika's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
XTRA:SAC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 40 Stocks 3.2%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

XTRA:SAC Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-09-30
2023-09-30
2022-09-30
2021-09-30
2020-09-30
2019-09-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SANOCHEMIA Pharmazeutika has not reported any payouts.
  • Unable to verify if SANOCHEMIA Pharmazeutika's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SANOCHEMIA Pharmazeutika's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SANOCHEMIA Pharmazeutika has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SANOCHEMIA Pharmazeutika's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SANOCHEMIA Pharmazeutika afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SANOCHEMIA Pharmazeutika has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SAC Management

 What is the CEO of SANOCHEMIA Pharmazeutika's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Timo Bender
TENURE AS CEO 1.2 years
CEO Bio

Mr. Timo Bender has been Chief Executive Officer of Sanochemia Pharmazeutika AG since February 1, 2019 and serves as its Chief Production and Human Resource Officer. He serves as Member of Management Board at SANOCHEMIA Pharmazeutika AG.

CEO Compensation
  • Insufficient data for Timo to compare compensation growth.
  • Insufficient data for Timo to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the SANOCHEMIA Pharmazeutika management team in years:

5.4
Average Tenure
  • The average tenure for the SANOCHEMIA Pharmazeutika management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Werner Frantsits

TITLE
Founder & Member of the Supervisory Board

Timo Bender

TITLE
CEO, Chief Production & Human Resource Officer and Member of Management Board
TENURE
1.2 yrs

Stefan Welzig

TITLE
CFO, Chief Technical Officer
TENURE
7.3 yrs

Klaus Gerdes

TITLE
CMO and Member of the Mgmt Board for Mktg & Sales
TENURE
8.3 yrs

Christina Abrahamsberg

TITLE
CSO and Member of the Management Board for Research & Development & Quality Management
TENURE
3.5 yrs
Board of Directors

Sabine Kirchmayr-Schliesselberger

TITLE
Chairman of Supervisory Board
TENURE
1.6 yrs

Werner Frantsits

TITLE
Founder & Member of the Supervisory Board

Anton Dallos

TITLE
Member of the Supervisory Board
AGE
72

Elke Napokoj

TITLE
Member of the Supervisory Board

Felix Epper

TITLE
Member of the Supervisory Board

Jürgen Feuerstein

TITLE
Member of the Supervisory Board
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess SANOCHEMIA Pharmazeutika's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SANOCHEMIA Pharmazeutika has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SAC News

Simply Wall St News

Is SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Balance Sheet A Threat To Its Future?

While small-cap stocks, such as SANOCHEMIA Pharmazeutika AG (ETR:SAC) with its market cap of €15m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is

Simply Wall St -

What You Must Know About SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Financial Strength

Investors are always looking for growth in small-cap stocks like SANOCHEMIA Pharmazeutika AG (ETR:SAC), with a market cap of €24.46m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Is SANOCHEMIA Pharmazeutika AG's (ETR:SAC) PE Ratio A Signal To Buy For Investors?

This analysis is intended to introduce important early concepts to people who are starting to invest. … and want to begin learning the link between SANOCHEMIA Pharmazeutika AG (ETR:SAC)’s fundamentals and stock market performance. … SANOCHEMIA Pharmazeutika AG (ETR:SAC) is trading with a trailing P/E of 16.6x, which is lower than the industry average of 22x.

Simply Wall St -

Will SANOCHEMIA Pharmazeutika AG (ETR:SAC) Continue To Underperform Its Industry?

View our latest analysis for SANOCHEMIA Pharmazeutika Breaking down Return on Equity Return on Equity (ROE) is a measure of SANOCHEMIA Pharmazeutika’s profit relative to its shareholders’ equity. … Since SANOCHEMIA Pharmazeutika’s return does not cover its cost, with a difference of -5.03%, this means its current use of equity is not efficient and not sustainable. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity XTRA:SAC Last Perf Jun 5th 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management.

Simply Wall St -

Does SANOCHEMIA Pharmazeutika AG (ETR:SAC) Fall With The Market?

If you are looking to invest in SANOCHEMIA Pharmazeutika AG’s (XTRA:SAC), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your portfolio. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … SAC’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio.

Simply Wall St -

Why SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Ownership Structure Is Important

However, a higher level of insider ownership has been linked to management executing on high-returning projects instead of expansion projects for the sake of apparent growth. … This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Thus, potential investors should look into these business relations and check how it can impact long-term shareholder returns.Next Steps: Institutional ownership in SAC is not at a level that would concern investors.

Simply Wall St -

What does SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Balance Sheet Tell Us About Its Future?

Moreover, SAC has produced cash from operations of €1.27M over the same time period, resulting in an operating cash to total debt ratio of 8.11%, meaning that SAC’s current level of operating cash is not high enough to cover debt. … At the current liabilities level of €14.13M liabilities, the company has been able to meet these commitments with a current assets level of €27.54M, leading to a 1.95x current account ratio. … Risk around debt is very low for SAC, and the company also has the ability and headroom to increase debt if needed going forward.Next Steps: SAC’s cash flow coverage indicates it could improve its operating efficiency in order to meet demand for debt repayments should unforeseen events arise.

Simply Wall St -

Was SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Earnings Growth Better Than The Industry's?

Measuring SANOCHEMIA Pharmazeutika AG's (XTRA:SAC) track record of past performance is a useful exercise for investors. … View our latest analysis for SANOCHEMIA Pharmazeutika Commentary On SAC's Past Performance To account for any quarterly or half-yearly updates, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … XTRA:SAC Income Statement Mar 19th 18 We can further analyze SANOCHEMIA Pharmazeutika's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Have Investors Priced In SANOCHEMIA Pharmazeutika AG's (ETR:SAC) Growth?

It’s trading around 10.81% below my intrinsic value, which means if you buy SANOCHEMIA Pharmazeutika today, you’d be paying a fair price for it. … Furthermore, it seems like SANOCHEMIA Pharmazeutika’s share price is quite stable, which means there may be less chances to buy low in the future now that it’s fairly valued. … It seems like the market has already priced in SAC’s positive outlook, with shares trading around its fair value.

Simply Wall St -

SAC Company Info

Description

SANOCHEMIA Pharmazeutika AG, a specialty pharmaceuticals company, develops and manufactures drugs and diagnostics in the areas of neurodegeneration, pain, and oncology. It offers active pharmaceutical ingredients; sterile and semi-sterile liquid, and semi-liquid presentations, such as antibiotics and hormones; clinical diagnostics; and veterinary pharmaceuticals, as well as radiological products, including a range of X-ray imaging agents and the MRT imaging agents. The company’s products include tolperisone, a muscle relaxant; and galantamine that is used in an Alzheimer's disease. It also researches and develops in therapeutic areas, such as painful muscle spasms/spasticity, and bladder cancer diagnostics; and offers contract manufacturing services. The company was founded in 1990 and is headquartered in Vienna, Austria.

Details
Name: SANOCHEMIA Pharmazeutika AG
SAC
Exchange: XTRA
Founded: 1990
€1,073,578
15,649,831
Website: http://www.sanochemia.at
Address: SANOCHEMIA Pharmazeutika AG
Boltzmanngasse 11,
Vienna,
Vienna, 1090,
Austria
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA SAC Ordinary Shares XETRA Trading Platform DE EUR 12. May 1999
DB SAC Ordinary Shares Deutsche Boerse AG DE EUR 12. May 1999
BRSE SAC Ordinary Shares Berne Stock Exchange CH CHF 12. May 1999
Number of employees
Current staff
Staff numbers
152
SANOCHEMIA Pharmazeutika employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:02
End of day share price update: 2020/02/03 00:00
Last estimates confirmation: 2019/12/10
Last earnings filing: 2019/05/23
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.